Orchestra BioMed Holdings, Inc. (OBIO)
NASDAQ: OBIO · Real-Time Price · USD
2.780
-0.200 (-6.71%)
At close: Jun 27, 2025, 4:00 PM
2.920
+0.140 (5.04%)
After-hours: Jun 27, 2025, 7:10 PM EDT
Orchestra BioMed Holdings Revenue
Orchestra BioMed Holdings had revenue of $868.00K in the quarter ending March 31, 2025, with 40.00% growth. This brings the company's revenue in the last twelve months to $2.89M, up 30.23% year-over-year. In the year 2024, Orchestra BioMed Holdings had annual revenue of $2.64M, down -4.42%.
Revenue (ttm)
$2.89M
Revenue Growth
+30.23%
P/S Ratio
38.78
Revenue / Employee
$41,229
Employees
70
Market Cap
106.51M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2.64M | -122.00K | -4.42% |
Dec 31, 2023 | 2.76M | -773.00K | -21.88% |
Dec 31, 2022 | 3.53M | 4.32M | -551.79% |
Dec 31, 2021 | -782.00K | -6.49M | -113.71% |
Dec 31, 2020 | 5.70M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
OBIO News
- 10 days ago - Orchestra BioMed Showcases AVIM Therapy as Purpose-Built Solution for Hypertensive Heart Disease at CSI Frankfurt 2025 - GlobeNewsWire
- 4 weeks ago - Orchestra BioMed: Two Best-In-Class Devices And Promising Partnerships - Seeking Alpha
- 6 weeks ago - Orchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical Milestones - GlobeNewsWire
- 7 weeks ago - Orchestra BioMed's AVIM Therapy Global Intellectual Property Estate Reaches 137 Issued Patents for the Treatment of Hypertension and Heart Failure - GlobeNewsWire
- 2 months ago - Orchestra BioMed Receives FDA Approval of IDE to Initiate U.S. Coronary Pivotal Trial Randomizing First-in-Class Sirolimus-AngioInfusion Balloon, Virtue SAB, Head-to-Head with Paclitaxel-Coated Balloon - GlobeNewsWire
- 2 months ago - Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences - GlobeNewsWire
- 2 months ago - Orchestra BioMed Announces AVIM Therapy-Focused Satellite Symposium at HRS 2025 Annual Meeting - GlobeNewsWire
- 2 months ago - Orchestra BioMed Receives FDA Breakthrough Device Designation for AVIM Therapy - GlobeNewsWire